Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Ascletis Completes Bridging Study of One-Pill Combination HCV Treatment

publication date: Aug 21, 2020

Ascletis Pharma successfully completed a bridging study of ASC18, a one-pill, once-a-day fixed dose combination of two hepatitis C treatments. ASC18 consists of 200 mg ravidasvir (RDV) and 400 mg sofosbuvir (SOF). Sofosbuvir is Gilead's Solvadi, a well-known HCV treatment. In the Phase I trial, the fixed dose combination showed similar efficacy and safety to Ascletis' previously approved two pill regimen of the two drugs. Ascletis said ASC18 will improve its competitive profile for HCV. More details....

Stock Symbol: (HK: 1672)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.